US Stem Cell (USRM) Stock Price

US Stem Cell Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 2.6% per year over the past 19 years to 82,100.00 USD. US Stem Cell's net margin stands at -3,481.0%, down from -32.2% several years earlier.

US Stem Cell stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of US Stem Cell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how US Stem Cell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing US Stem Cell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

US Stem Cell Stock Price History
DateUS Stem Cell Price
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/19/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
8/7/20250.00 USD
8/6/20250.00 USD
8/5/20250.00 USD
8/4/20250.00 USD
8/1/20250.00 USD
7/31/20250.00 USD
7/30/20250.00 USD
7/29/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

US Stem Cell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2015
2.19 M USD
-2.61 M USD
-1.64 M USD
Jan 1, 2016
3.08 M USD
-1.16 M USD
-2.07 M USD
Jan 1, 2017
5.52 M USD
-804,700.00 USD
-3.48 M USD
Jan 1, 2018
6.70 M USD
-1.10 M USD
-2.16 M USD
Jan 1, 2019
3.07 M USD
-2.72 M USD
-3.84 M USD
Jan 1, 2020
277,100.00 USD
-2.40 M USD
-2.89 M USD
Jan 1, 2021
200,800.00 USD
-2.14 M USD
-3.29 M USD
Jan 1, 2022
82,100.00 USD
-1.72 M USD
-2.86 M USD

US Stem Cell Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 28, 2026, 11:31 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2007200820092010201120122013201420152016201720182019202020212022
–––––––2.002.003.005.006.003.00–––
–––––––––50.0066.6720.00-50.00–––
–––––––50.0050.0066.6760.0066.6733.33–––
1.001.001.001.001.001.001.001.001.002.003.004.001.001.001.001.00
-14.00-11.00-4.00-3.00-2.00-2.00-2.00-3.00-2.00-1.00–-1.00-2.00-2.00-2.00-1.00
–––––––-150.00-100.00-33.33–-16.67-66.67–––
-18.00-14.00-3.00-5.00-4.00-4.00-3.00-2.00-1.00-2.00-3.00-2.00-3.00-2.00-3.00-2.00
38.46-22.22-78.5766.67-20.00–-25.00-33.33-50.00100.0050.00-33.3350.00-33.3350.00-33.33
0.010.010.020.030.060.150.250.490.9124.15309.01365.64398.04429.29460.79591.56
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales US Stem Cell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue US Stem Cell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare US Stem Cell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares US Stem Cell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against US Stem Cell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

US Stem Cell stock margins

The US Stem Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of US Stem Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for US Stem Cell.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2015
55.60 %
-118.92 %
-74.93 %
Jan 1, 2016
68.48 %
-37.61 %
-67.15 %
Jan 1, 2017
65.85 %
-14.58 %
-63.06 %
Jan 1, 2018
68.50 %
-16.38 %
-32.24 %
Jan 1, 2019
56.54 %
-88.46 %
-124.83 %
Jan 1, 2020
76.87 %
-866.19 %
-1,043.13 %
Jan 1, 2021
74.05 %
-1,063.70 %
-1,637.15 %
Jan 1, 2022
71.01 %
-2,095.62 %
-3,481.00 %

US Stem Cell Stock Revenue, EBIT, Earnings per Share

The US Stem Cell earnings per share therefore indicates how much revenue US Stem Cell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2015
2.40 USD
-2.86 USD
-1.80 USD
Jan 1, 2016
0.13 USD
-0.05 USD
-0.09 USD
Jan 1, 2017
0.02 USD
-0.00 USD
-0.01 USD
Jan 1, 2018
0.02 USD
-0.00 USD
-0.01 USD
Jan 1, 2019
0.01 USD
-0.01 USD
-0.01 USD
Jan 1, 2020
0.00 USD
-0.01 USD
-0.01 USD
Jan 1, 2021
0.00 USD
-0.00 USD
-0.01 USD
Jan 1, 2022
0.00 USD
-0.00 USD
-0.00 USD

US Stem Cell business model & stock analysis

US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry.

US Stem Cell SWOT Analysis

Strengths

US Stem Cell Inc possesses several key strengths:

  • Strong Intellectual Property: US Stem Cell Inc has a robust portfolio of intellectual property, including patents and proprietary technology, which enables them to maintain a unique position in the stem cell industry.
  • Advanced Research and Development: The company has a dedicated team of scientists and researchers who are continuously exploring and developing innovative stem cell therapies, ensuring the company remains at the forefront of the field.
  • Solid Track Record: US Stem Cell Inc has a successful track record in developing and commercializing stem cell therapies for various medical conditions, building confidence and trust in their capabilities.
  • Established Partnerships: The company has established strategic partnerships and collaborations with leading academic institutions and healthcare organizations, providing access to resources, expertise, and potential avenues for growth.

Weaknesses

Despite their strengths, US Stem Cell Inc also faces certain weaknesses:

  • Regulatory Challenges: The stem cell industry is subject to strict regulations and oversight, which can present challenges in obtaining necessary approvals for product development and commercialization.
  • Limited Market Reach: While US Stem Cell Inc has made significant strides, the market for stem cell therapies is still relatively niche. This limited market reach may impact the company's potential for widespread adoption and revenue generation.
  • Dependency on Research Funding: Continued research and development activities require substantial funding, and US Stem Cell Inc may face difficulties in securing sufficient funding to support their ambitious pipeline of therapies.

Opportunities

US Stem Cell Inc can capitalize on the following opportunities:

  • Emerging Market Demand: As awareness and acceptance of stem cell therapies grow, there is an increasing demand for innovative treatments. US Stem Cell Inc can capture this growing market by continuously developing and introducing novel therapies.
  • Global Expansion: The company can explore opportunities to expand their reach internationally, targeting regions with a favorable regulatory environment and unmet medical needs, thereby diversifying their revenue streams.
  • Strategic Partnerships: Forming strategic alliances with pharmaceutical companies or healthcare providers can accelerate the commercialization process, enhance market access, and provide additional resources for research and development.

Threats

US Stem Cell Inc must navigate the following threats:

  • Competition: The stem cell industry is becoming increasingly competitive, with the emergence of new players and potential breakthroughs from competitors. US Stem Cell Inc must differentiate itself through continued innovation and effective marketing strategies.
  • Legal and Ethical Concerns: The use of stem cells raises legal and ethical debates, which may result in stricter regulations or even public opposition. US Stem Cell Inc must stay ahead of potential changes and work transparently to maintain public trust.
  • Technological Challenges: Advancements in alternative technologies or treatment modalities could disrupt the stem cell industry. It is crucial for US Stem Cell Inc to stay updated with scientific advancements and adapt accordingly.

US Stem Cell Segments

US Stem Cell Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

Service
Product
Management Fees-related Party
Details
Date
Service
Product
Management Fees-related Party
Jan 1, 2018
5.04 M USD
1.66 M USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
378,621.00 USD
50,751.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
209,696.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
180,894.00 USD
0.00 USD

US Stem Cell Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

US Stem Cell historical P/E ratio, EBIT multiple, and P/S ratio

US Stem Cell annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

US Stem Cell shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2015
912,100.00 Stocks
Jan 1, 2016
24.15 M Stocks
Jan 1, 2017
309.01 M Stocks
Jan 1, 2018
365.64 M Stocks
Jan 1, 2019
398.04 M Stocks
Jan 1, 2020
429.29 M Stocks
Jan 1, 2021
460.79 M Stocks
Jan 1, 2022
591.56 M Stocks

US Stem Cell stock splits

In US Stem Cell's history, there have been no stock splits.
Price targets and forecasts for US Stem Cell are not yet available.

US Stem Cell shareholder structure

% Name
6.84368%
Northstar Biotech Group, L.L.C.
Northstar Biotech Group, L.L.C.
4.93189%
Knutson (Gregory)
Knutson (Gregory)
0.08908%
Borman (Mark P)
Borman (Mark P)
0.01073%
Murphy (William P Jr., M.D.)
Murphy (William P Jr., M.D.)
0.00140%
Tomas (Mike)
Tomas (Mike)
0.00033%
Anderson (Sheldon T)
Anderson (Sheldon T)

US Stem Cell Executives and Management Board

MT

Mr. Mike Tomas

(58)

President, Chief Executive Officer, Chief Financial Officer, Director · since 2003

Compensation327,279.00 USD
MB

Mr. Mark Borman

(68)

Non-Executive Chairman of the Board · since 2009

WM

Dr. William Murphy

(99)

Chairman Emeritus · since 2003

SA

Mr. Sheldon Anderson

(72)

Director

GK

Mr. Gregory Knutson

(71)

Director

Frequently asked questions about US Stem Cell

The business model of US Stem Cell Inc is centered around the development and commercialization of innovative cell therapy products and services. As a biotechnology company, US Stem Cell Inc focuses on advancing regenerative medicine to provide potential treatments for various medical conditions. Their approach involves extracting stem cells from the patient's own adipose tissue, which are then processed to develop personalized treatment options. By leveraging their proprietary technology and expertise, US Stem Cell Inc aims to offer therapeutic solutions for individuals seeking alternative and potentially more effective medical treatments.

All fundamentals and in-depth analysis of US Stem Cell

Our stock analysis for US Stem Cell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of US Stem Cell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

US Stem Cell Stock
US Stem Cell Revenue→
US Stem Cell Stock
US Stem Cell Net Income→
US Stem Cell Stock
US Stem Cell P/E→
US Stem Cell Stock
US Stem Cell P/S→
US Stem Cell Stock
US Stem Cell EBIT→
US Stem Cell Stock
US Stem Cell Dividend→
US Stem Cell Stock
US Stem Cell Directors Dealings→
US Stem Cell Stock
US Stem Cell Stocks→
US Stem Cell Stock
US Stem Cell Market capitalization→
US Stem Cell Stock
US Stem Cell Debt→
US Stem Cell Stock
US Stem Cell Liabilities→
US Stem Cell Stock
US Stem Cell Equity→
US Stem Cell Stock
US Stem Cell AAQS→
US Stem Cell Stock
US Stem Cell Employees→
US Stem Cell Stock
US Stem Cell ROE→
US Stem Cell Stock
US Stem Cell ROA→
US Stem Cell Stock
US Stem Cell ROCE→
US Stem Cell Stock
US Stem Cell News→
US Stem Cell Stock
US Stem Cell Analyst Price Targets→

Health Stocks

UscomUS Physical TherapyUtah Medical ProductsUrtesteVaccinexUrogen PharmaVaidya Sane Ayurved LaboratoriesUpstream BioVaishali PharmaUpHealthValbiotisUniverse PharmaceuticalsAll Stocks A–Z →